Compare AbCellera Biologics Inc (ABCL) vs Dow Inc (DOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Dow Inc — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Dow Inc trades at $29.35 (market cap $20.64B). The key difference: Dow Inc is far larger — about 8.8× AbCellera Biologics Inc's market cap, and Dow Inc pays a 4.89% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DOW | |
|---|---|---|
Market Cap | $2.35B | $20.64B |
Sector | Health | Basic Materials |
52-Week High | $8.12 | $41.87 |
52-Week Low | $2.78 | $20.65 |
Enterprise Value | $1.99B | $36.42B |
Dividend Yield | — | 4.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
DOW trades at $28.64, up 3.36% today, with a bearish technical signal despite recent earnings beats. The stock shows negative profitability with a net income margin of -7.24% and ROE of -17.85%, though valuation ratios like P/S of 0.5 appear modest. Cash flow trends indicate operational challenges, with 2025 operating cash flow at $1.03B down from prior years, while the company maintains a dividend payout.
Outlook remains cautious due to weak fundamentals and bearish technicals, but analyst consensus price target of $36.11 suggests 26% upside. Key risks include sustained negative margins and high debt levels, while potential catalysts hinge on cost-cutting effectiveness and market demand recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
